Cellbxhealth Plc · LSE:CLBX
Cellbxhealth — ANGLE — Shares Cenkos Growth & Innovation Forum (January 2017)
13 slides from Cellbxhealth's conference presentation, Jan 31, 2017
Slide 1: Parsortix Liquid Biopsy
Parsortix Liquid Biopsy Shares Cenkos Growth & Innovation Forum Andrew Newland 31 January 2017 © ANGLE plc 2017 Page 1
Slide 2: Legal disclaimer
Legal disclaimer LSE AIM: AGL OTCQX: ANPCY This presentation has been prepared by ANGLE plc (the “Company”). By attending this presentation and/or reviewing the slides you agree to be bound by the following conditions. The information and opinions contained in this presentation have not been indepen
Slide 3: Liquid biopsy improving healthcare and reducing costs: driving precision medicine
Liquid biopsy improving healthcare and reducing costs: driving precision medicine Cancer Research UK: “One in two people born after 1960 in the UK will be diagnosed with some form of cancer during their lifetime.” Each patient’s cancer is different Big pharma developing more selective drugs: Patient
Slide 4: Animation showing Parsortix patented steps
Animation showing Parsortix patented steps © ANGLE plc 2017 Page 4
Slide 5: Video showing blood flowing in Parsortix cassette
Video showing blood flowing in Parsortix cassette © ANGLE plc 2017 Page 5
Slide 6: ANGLE differentiation
ANGLE differentiation The Complete Picture Intact CTCs not just ctDNA. Compatible with all downstream analysis techniques Evidence-based driven by KOLs and clinical studies Patented product solution Overcomes problems with service labs Scaleable business with third party manufacture Page 6 © ANGLE p
Slide 7: Growing research use sales
Growing research use sales First sales achieved FY16 Targeting sales to leading cancer centres − broaden range of users of the system with additional posters, publications and clinical evidence Sales pipeline increasing − new clinical applications and companion diagnostics Cancer Research UK contrac
Slide 8: Ovarian cancer clinical application in development
Ovarian cancer clinical application in development Ovarian sales potential >£300m p.a. Medical University of Vienna 65 100% 100% In US, 200,000 women p.a. have surgery on abnormal pelvic masses 95% 92% ParsortixTM test to triage patients to Local Specialist 90% target identify appropriate treatment
Slide 9: Ovarian cancer clinical studies
Ovarian cancer clinical studies 200 patient European study (ANG-001) European study >95% patient enrolled, due to − Medical University of Vienna, Charité and Vivantes complete enrolment in February 2017 200 patient United States study (ANG-003) US Study 70% patient enrolled, due to complete − Univer
Slide 10: FDA authorisation progress
FDA authorisation progress Potential to be first FDA cleared system for ANG-002 clinical study plan developed in harvesting cancer cells from blood consultation with three world-class US breast cancer centres Success will position Parsortix as the gold − designed to meet FDA remaining requirements s
Slide 11: Other key areas of development
Other key areas of development Breast cancer blood test alternative to invasive metastatic biopsy (RNA) − successful pilot study by University of Southern California − FDA study being extended to cover this form of analysis − clinical data expected in CY17 Prostate cancer blood test alternative to p
Slide 12: Summary
Summary Liquid biopsy ParsortixTM patented system seeking a leading position in emerging $ multi-billion liquid biopsy market Providing the Complete Picture (intact CTCs not just ctDNA) Ovarian cancer clinical studies headline data due Q2, CY17 FDA study to support metastatic breast cancer clearance
Slide 13: ANGLE plc
ANGLE plc ANGLE Europe Ltd ANGLE North America Inc 3 Frederick Sanger Road 3711 Market Street The Surrey Research Park University Science Center 8th floor Guildford GU2 7YD Philadelphia PA 19104 United Kingdom USA Website: www.ANGLEplc.com © ANGLE plc 2017 Page 13
ANGLE — Shares Cenkos Growth & Innovation Forum (January 2017) on 6ix